LAUSR

&NA; Mirabegron is a &bgr;3‐adrenoceptor agonist and released on the marked for the treatment of overactive bladder. Because mirabegron is the only &bgr;3‐adrenoceptor agonist available and substances that increase the levels of cyclic adenosine monophosphate (cAMP) inhibit platelet activity, we tested the hypothesis that mirabegron could have antiplatelet activity. Collagen‐ and thrombin induced platelet aggregation, thromboxane B2 (TXB2) and cyclic nucleotides quantification and calcium (Ca2+) mobilization were determined in the absence and presence of mirabegron in human washed platelets. Our results revealed that mirabegron (10−300 &mgr;M) produced significant inhibitions on platelet aggregation induced by collagen‐ or thrombin, accompanied by greater intracellular levels of cAMP. The &bgr;3‐adrenoceptor antagonist L 748,337 (1 &mgr;M) and the adenylate cyclase inhibitor, SQ 22,536 (100 &mgr;M) reversed the inhibition induced by mirabegron in thrombin‐stimulated platelets. The selective antagonists for &bgr;1‐and &bgr;2‐adrenoceptors, atenolol and ICI 117,551 (3 &mgr;M), respectively did not interfere on the inhibition induced by mirabegron. In Fluo‐4 loaded platelets, mirabegron reduced the total and intracellular Ca2+ levels. Pre‐incubation with mirabegron almost abolished the levels of TXB2. Mirabegron did not augment the intracellular levels of cyclic guanosine monophosphate. In conclusion, mirabegron inhibited human platelet aggregation through cAMP accumulation, thus suggesting that substances that activate &bgr;3‐adrenoceptor could be beneficial as adjuvant antiplatelet therapy.